Dermatologic Toxicities Associated With Novel Pan‐ RAS / RAF Inhibitors
Journal of Cutaneous Pathology · 2026
DOI: 10.1111/cup.70159 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, 2026. Verfasst von Lin J He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Eruptions, Neoplasms, raf Kinases. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging. Therefore, knowledge of the morphologic patterns of DTs from pan‐RAS/RAF inhibitors will enable quick diagnosis and appropriate management.
Methods
The clinical and histologic features of patients treated with pan‐RAS or pan‐RAF inhibitors for advanced stage RAS mutated malignancies were retrospectively reviewed.
Results
Associated DTs were identified in eight patients treated with either pan‐RAS ( n = 4) or pan‐RAF ( n = 4) plus MEK/ERK inhibitors for RAS mutated tumors (colorectal, lung, pancreatic, thyroid, melanoma). The patients ranged from 37 to 72 years of age. Five patients had initial clinical presentation of an acneiform eruption complicated by ulceration, flaccid vesicles, or diffuse exfoliative erythroderma. Maculopapular eruption, purpuric patches and papules, and eruptive dark nevi were the other clinical presentations. Skin biopsies were primarily inflammatory with histopathologic features of suppurative folliculitis ( n = 2), dermal hypersensitivity reaction ( n = 2), subcorneal acantholytic dermatosis ( n = 1), subcorneal pustules ( n = 1), ulcer ( n = 1), and eruptive nevi ( n = 1).
Conclusions
Treatment with novel pan‐RAS/RAF inhibitors exhibits a spectrum of DTs that exhibit some overlap with small molecule inhibitors that target the MAPK pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Fiorinda Muhaj, Carlos A Torres-Cabala, Victor G Prieto
Zitieren
APA
He, L. J., Hegazy, S., Aung, P. P., Nagarajan, P., Muhaj, F., Choksi, A. N., Ciurea, A. M., Nelson, K. C., Ivan, D., Torres-Cabala, C. A., Prieto, V. G., & Curry, J. L. (2026). Dermatologic Toxicities Associated With Novel Pan‐ RAS / RAF Inhibitors. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.70159
Vancouver
He LJ, Hegazy S, Aung PP, Nagarajan P, Muhaj F, Choksi AN, et al. Dermatologic Toxicities Associated With Novel Pan‐ RAS / RAF Inhibitors. Journal of Cutaneous Pathology. 2026. doi:10.1111/cup.70159
BibTeX
@article{He2026,
author = {He, Lin J and Hegazy, Shaymaa and Aung, Phyu P and Nagarajan, Priyadharsini and Muhaj, Fiorinda and Choksi, Adrienne N and Ciurea, Ana M and Nelson, Kelly C and Ivan, Doina and Torres-Cabala, Carlos A and Prieto, Victor G and Curry, Jonathan L},
title = {Dermatologic Toxicities Associated With Novel Pan‐ RAS / RAF Inhibitors},
journal = {Journal of Cutaneous Pathology},
year = {2026},
doi = {10.1111/cup.70159}
}
EUVIMED